Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track AURA with free AI briefings, catalyst countdowns, and dilution alerts.

AURA · Aura Biosciences, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$297.2M Cash on Hand
30.3mo Cash Runway
Follow AURA by email Get an email when AURA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about AURA, unsubscribe in one click. Privacy

📣 What AURA Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Belzupacap Sarotalocan (AU-011) Choroidal Melanoma Phase 3 · NCT06007690 Active not recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

AURA holds $297.2M in cash and short-term investments (as of Sep 30, 2026) and burns about $29.5M/quarter from operations, an estimated runway of 30.3 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 30 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AURA files for a raise →

👥 Who Owns AURA

Insiders 3.9% Other 5%+ holders 20.6% Institutions (203 holders) 75.5% Public and other holders 0%
HolderTypeShares% of sharesAs of
Chen Yu 5%+ holder (13G) 10,422,733 10.01% 2026-09-30
Adage Capital Management, L.P. Institution (13G, 5%+) 9,104,294 8.75% 2026-06-30
Frazier Life Sciences Public Fund, L.P. 5%+ holder (13G) 5,807,260 5.58% 2026-06-30
ADAR1 Capital Management, LLC Institution (13G, 5%+) 5,385,879 5.18% 2026-09-30
ForGrowth III PA B.V. 5%+ holder (13G) 5,248,841 5.04% 2026-09-25
BlackRock, Inc. Institution (13G, 5%+) 5,219,492 5.02% 2026-09-30
Natalie C. Holles
Chief Executive Officer and President, D · +2.17M options
Insider 1,153,962 1.11% 2026-05-19
los Pinos Elisabet de
President and Chief Executive Officer, D · +249,000 options
Insider 703,578 0.68% 2026-03-02
David Michael Johnson
Director · +47,000 options
Insider 483,839 0.46% 2026-06-11
Janet Jill Hopkins
Chief Medical Officer · +277,094 options
Insider 363,287 0.35% 2026-11-16
Anthony S Gibney
Chief Financial and Business Officer. · +128,755 options
Insider 265,354 0.25% 2026-06-16
Mark Plavsic
Chief Technology Officer · +112,661 options
Insider 243,736 0.23% 2026-03-02

Share count 104,074,302 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full AURA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AURA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.